AU2017210224B2 - Treatment of cancer with combinations of immunoregulatory agents - Google Patents

Treatment of cancer with combinations of immunoregulatory agents Download PDF

Info

Publication number
AU2017210224B2
AU2017210224B2 AU2017210224A AU2017210224A AU2017210224B2 AU 2017210224 B2 AU2017210224 B2 AU 2017210224B2 AU 2017210224 A AU2017210224 A AU 2017210224A AU 2017210224 A AU2017210224 A AU 2017210224A AU 2017210224 B2 AU2017210224 B2 AU 2017210224B2
Authority
AU
Australia
Prior art keywords
cells
antibody
cancer
tumor
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017210224A
Other languages
English (en)
Other versions
AU2017210224A1 (en
Inventor
Mark P. Chao
Doris Po Yi HO
Ravindra Majeti
Melissa N. MCCRACKEN
Kelly Marie MCKENNA
Jens-Peter VOLKMER
Irving L. Weissman
Stephen WILLINGHAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of AU2017210224A1 publication Critical patent/AU2017210224A1/en
Application granted granted Critical
Publication of AU2017210224B2 publication Critical patent/AU2017210224B2/en
Priority to AU2024202900A priority Critical patent/AU2024202900A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AU2017210224A 2016-01-21 2017-01-20 Treatment of cancer with combinations of immunoregulatory agents Active AU2017210224B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024202900A AU2024202900A1 (en) 2016-01-21 2024-05-02 Treatment of cancer with combinations of immunoregulatory agents

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662281571P 2016-01-21 2016-01-21
US62/281,571 2016-01-21
US201662301981P 2016-03-01 2016-03-01
US62/301,981 2016-03-01
PCT/US2017/014375 WO2017127707A1 (en) 2016-01-21 2017-01-20 Treatment of cancer with combinations of immunoregulatory agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024202900A Division AU2024202900A1 (en) 2016-01-21 2024-05-02 Treatment of cancer with combinations of immunoregulatory agents

Publications (2)

Publication Number Publication Date
AU2017210224A1 AU2017210224A1 (en) 2018-08-02
AU2017210224B2 true AU2017210224B2 (en) 2024-02-08

Family

ID=59360269

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017210224A Active AU2017210224B2 (en) 2016-01-21 2017-01-20 Treatment of cancer with combinations of immunoregulatory agents
AU2024202900A Pending AU2024202900A1 (en) 2016-01-21 2024-05-02 Treatment of cancer with combinations of immunoregulatory agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024202900A Pending AU2024202900A1 (en) 2016-01-21 2024-05-02 Treatment of cancer with combinations of immunoregulatory agents

Country Status (9)

Country Link
US (3) US20170210803A1 (enExample)
EP (2) EP4070812A1 (enExample)
JP (3) JP7026047B2 (enExample)
KR (1) KR102833922B1 (enExample)
CN (1) CN109071676A (enExample)
AU (2) AU2017210224B2 (enExample)
CA (1) CA3011429A1 (enExample)
SG (1) SG11201806110QA (enExample)
WO (1) WO2017127707A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3011097C (en) 2016-01-11 2022-12-20 Forty Seven, Inc. Humanized, mouse or chimeric anti-cd47 monoclonal antibodies
EP4194470A1 (en) * 2017-10-18 2023-06-14 Forty Seven, Inc. Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
PL4177270T3 (pl) * 2017-10-18 2024-11-18 Forty Seven, Inc. Terapia nowotworu złośliwego jajnika w oparciu o środek anty-cd47
AR113862A1 (es) 2017-12-01 2020-06-17 Seattle Genetics Inc Anticuerpos anti-cd47 y sus usos para tratar cáncer
WO2019109357A1 (zh) * 2017-12-08 2019-06-13 杭州翰思生物医药有限公司 抗pd-1/cd47的双特异性抗体及其应用
EP3752190B1 (en) 2018-02-12 2022-07-06 Forty Seven, Inc. Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies
SG11202102851XA (en) 2018-09-27 2021-04-29 Celgene Corp SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF
EP3860609A4 (en) * 2018-10-01 2022-08-03 Secura Bio, Inc. COMBINATION THERAPIES
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN109517073A (zh) * 2018-11-30 2019-03-26 北京泽勤生物医药有限公司 一种靶向治疗肿瘤的融合肽及其应用
US20220056135A1 (en) * 2018-12-21 2022-02-24 Ose Immunotherapeutics Bifunctional anti-pd-1/sirpa molecule
WO2020163692A1 (en) * 2019-02-08 2020-08-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway
CN113645980A (zh) * 2019-03-08 2021-11-12 北卡罗莱纳州立大学 用于增强的免疫疗法的生物响应抗体复合物
US20220288118A1 (en) * 2019-07-31 2022-09-15 Forty Seven, Inc. Depletion regimes for engineered t-cell or nk-cell therapy
JP7369297B2 (ja) 2019-12-17 2023-10-25 ファイザー・インク Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用
US20220251239A1 (en) * 2020-10-22 2022-08-11 Actinium Pharmaceuticals, Inc. Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
JP2023546679A (ja) * 2020-10-22 2023-11-07 アクティニウム ファーマシューティカルズ インコーポレイテッド がん治療における放射免疫療法とｃｄ４７遮断の併用
JP2024503822A (ja) * 2021-01-05 2024-01-29 ナショナル インスティテュート オブ バイオロジカル サイエンシズ，ベイジン Ｇｐｃ３及びｃｄ４７を標的とする二重特異性抗体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017068164A1 (en) * 2015-10-21 2017-04-27 Ose Immunotherapeutics Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
SI2477648T1 (sl) * 2009-09-15 2022-09-30 The Board Of Trustees Of The Leland Stanford Junior University Sinergijska terapija proti CD47 za krvne rake
KR20120107122A (ko) * 2009-12-22 2012-09-28 노파르티스 아게 치료법에서 사용하기 위한 ４가 ｃｄ４７―항체 불변 영역 융합 단백질
AU2011252851B2 (en) 2010-05-14 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to CD47
US10238698B2 (en) * 2012-01-25 2019-03-26 Dnatrix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
RU2693078C2 (ru) * 2012-12-03 2019-07-01 Новиммун С.А. Анти-cd47 антитела и способы их применения
MX2015007446A (es) * 2012-12-12 2015-12-07 Vasculox Inc Anticuerpos terapeuticos para cd47.
CN105189556A (zh) * 2013-03-15 2015-12-23 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
WO2016023001A1 (en) * 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
CN107459578B (zh) * 2016-05-31 2021-11-26 泰州迈博太科药业有限公司 一种靶向cd47与pd-l1的双功能融合蛋白

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017068164A1 (en) * 2015-10-21 2017-04-27 Ose Immunotherapeutics Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LUI, J. ET AL. "Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential" PLOS ONE (2015), 10(9), E0137345 *
M. N. MCCRACKEN ET AL: "Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 "Don't Eat Me" Signals", CLINICAL CANCER RESEARCH, vol. 21, no. 16, 26 June 2015, pages 3597-3601 *

Also Published As

Publication number Publication date
JP2022033899A (ja) 2022-03-02
KR102833922B1 (ko) 2025-07-15
KR20180102628A (ko) 2018-09-17
JP2019506400A (ja) 2019-03-07
WO2017127707A1 (en) 2017-07-27
JP2023085370A (ja) 2023-06-20
US20210230276A1 (en) 2021-07-29
JP7026047B2 (ja) 2022-02-25
AU2017210224A1 (en) 2018-08-02
EP4070812A1 (en) 2022-10-12
CN109071676A (zh) 2018-12-21
US20250066473A1 (en) 2025-02-27
SG11201806110QA (en) 2018-08-30
US20170210803A1 (en) 2017-07-27
CA3011429A1 (en) 2017-07-27
AU2024202900A1 (en) 2024-05-23
EP3405499A4 (en) 2020-03-18
EP3405499A1 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
US20250066473A1 (en) Treatment of cancer with combinations of immunoregulatory agents
US12030944B2 (en) Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
EP3697819B1 (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
HK40077720A (en) Treatment of cancer with combinations of immunoregulatory agents
HK40092424A (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
US20220119523A1 (en) Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway
CA2996167C (en) Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist
HK40036031A (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
HK40036031B (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
HK1257824B (en) Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)